



# ctos<sup>®</sup>

Connective Tissue Oncology Society

## 2018 Annual Meeting

November 14 - 17, 2018

Rome Cavalieri Hotel • Rome, Italy



### Wednesday, 14 November, 2018

12:00 pm - 6:00 pm

Registration

Salon de Cavalieri 1 & Gallery

6:00 pm - 8:00 pm

Welcome Reception

San Pietro Gallery

### Thursday, 15 November, 2018

6:00 am - 7:00 am

Registration

Salon de Cavalieri 1 & Gallery

7:00 am - 8:00 am

Coffee and Posters

Salon de Cavalieri 1 & Gallery

8:00 am - 5:30 pm

4th International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) -

"Collaboration in Sarcoma Care - Realizing Better Outcomes"

Caravaggio Room

9:00 am - 11:00 am

– SARC PROGRAM –

Salon del Cavalieri 2,3,4

#### Chawla/Rosenfeld Developmental Therapeutics Symposium

Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients

Introduction

**Elizabeth Lawlor, MD, PhD**

**Robert Maki, MD, PhD**

Enhancing Activity of B7-H3 CAR T Cells for Pediatric Sarcomas

**Robbie Majzner, MD**

Discussion / Q & A

Translating PARP Inhibition as a Therapeutic Target into Benefit for Patients with Sarcoma

**Sandra Strauss, MD, PhD**

Discussion / Q & A

Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities

**Keila Torres, MD, PhD**

Discussion / Q & A

2019 Career Development Update

**Elizabeth Lawlor, MD, PhD**



## SARC

collaborating to cure sarcoma

10:30 am - 11:00 am

Morning Coffee Break

Salon de Cavalieri 1 & Gallery

11:00 am - 11:30 am

OPENING REMARKS

Salon del Cavalieri 2,3,4

**Sarcoma of the Year: Intimal Sarcoma**

Moderators: **Olivier Mir** and **Elizabeth Baldini**

**Biology and Pathology of Intimal Sarcoma** – A. Paolo dei Tos

Paper 001

3042623

**SYSTEMIC TREATMENTS IN MDM2 + INTIMAL SARCOMA: A MULTICENTRE EXPERIENCE WITH ANTHRACYCLINE, GEMCITABINE AND PAZOPANIB WITHIN THE WORLD SARCOMA NETWORK (WSN)**

**Anna Maria Frezza**<sup>1</sup>; Tarek Assi<sup>2</sup>; Luigi Mariani<sup>3</sup>; Armelle Dufresne<sup>4</sup>; Siontis Brittany<sup>5</sup>; Kan Yonemori<sup>6</sup>; Emi Noguchi<sup>6</sup>; Eytan Ben-Amy<sup>7</sup>; Mrinal Gounder<sup>8</sup>; Robin Jones<sup>9</sup>; Pawel Teterycz<sup>10</sup>; Florence Duffaud<sup>12</sup>; Maria Abbondanza Pantaleo<sup>11</sup>; Vinod Ravi<sup>13</sup>; Bruno Vincenzi<sup>14</sup>; Giacomo Giulio Baldi<sup>15</sup>; Alexander Fedenko<sup>16</sup>; Hans Gelderblom<sup>17</sup>; Robert Maki<sup>18</sup>; Jean-Yves Blay<sup>4</sup>; Axel Le Cesne<sup>2</sup>; Scott Schuetze<sup>5</sup>; Paolo Casali<sup>1</sup>; Katherine Thornton<sup>7</sup>; Silvia Stacchiotti<sup>1</sup>

<sup>1</sup>Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; <sup>3</sup>Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Milan, Italy; <sup>4</sup>Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; <sup>5</sup>Department of Medicine, University of Michigan, Ann Arbor, MI, USA; <sup>6</sup>Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; <sup>7</sup>Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>9</sup>Sarcoma Unit, Royal Marsden NHS Foundation Trust/ Institute of Cancer Research, London, United Kingdom; <sup>10</sup>Maria Sklodowska-Curie Institute-Oncology Center, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland; <sup>11</sup>Sant'Orsola Malpighi Hospital, Department of Specialized, Experimental and Diagnostic Medicine, Bologna, Italy; <sup>12</sup>Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France; <sup>13</sup>Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Huston, TX, USA; <sup>14</sup>Medical Oncology, University Campus Bio-Medico, Rome, Italy; <sup>15</sup>Medical Oncology, Nuovo Ospedale "S.Stefano", Prato, Italy; <sup>16</sup>Medical Oncology, N.N. Blokhin Russian Cancer Research, Moscow, Russian Federation; <sup>17</sup>Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands; <sup>18</sup>Medical Oncology, Northwell Health and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Paper 002

3026957

**PRIMARY MALIGNANT SARCOMAS OF THE HEART AND GREAT VESSELS: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES**

**Luke Smith**<sup>1</sup>; Han Hsi Wong<sup>2</sup>; Marius Berman<sup>3</sup>; Dochka Davidson<sup>2</sup>; Gail Horan<sup>2</sup>; David Jenkins<sup>3</sup>; Helen Hatcher<sup>2</sup>

<sup>1</sup>School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; <sup>2</sup>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; <sup>3</sup>Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

Paper 003

3042337

**CLINICAL "REAL WORLD" NEXT GENERATION SEQUENCING REVEALS UNIQUE ABERRATIONS IN INTIMAL SARCOMA**

**Jason Roszik**; Anthony P. Conley; Roman Groisberg; Vinod Ravi; Roberto Carmagnani Pestana; Shiraj Sen; Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paper 004 3042847  
**OUTCOMES OF MULTIMODALITY TREATMENT WITH INDUCTION CHEMOTHERAPY, MAXIMAL RESECTION, AND PROTON BASED RADIATION THERAPY FOR CARDIAC AND PULMONARY VESSEL SARCOMAS**  
**Yen-Lin E. Chen**<sup>1</sup>; Rouyu Miao<sup>1</sup>; Edwin Choy<sup>2</sup>; Gregory M. Cote<sup>2</sup>; Thomas F. DeLaney<sup>1</sup>  
<sup>1</sup>Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>2</sup>Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA

Discussion – Robert Maki

1:00 pm - 2:00 pm

Lunch

Belle Arti & Garden Lobby

2:00 pm - 3:30 pm

– SESSION 2 –

Salon del Cavaliere 2,3,4

### Soft Tissue Sarcoma: Chemotherapy

Moderators: **Wei-Wu (Tom) Chen** and **Claudia Valverde**

Paper 005 3042630  
**THE IMPACT OF CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH EXTREMITY AND TRUNK WALL SOFT TISSUE SARCOMA: REVISITING THE RESULTS OF THE EORTC-STBSG 62931 RANDOMISED TRIAL USING SARculator, A VALIDATED NOMOGRAM-BASED RISK ASSESSMENT TOOL**  
**Sandro Pasquali**<sup>1</sup>; Sara Pizzamiglio<sup>2</sup>; Nathan Touati<sup>2</sup>; Saskia Litiere<sup>2</sup>; Sandrine Marreaud<sup>2</sup>; Bernd Kasper<sup>3</sup>; Hans Gelderblom<sup>4</sup>; Silvia Stacchiotti<sup>1</sup>; Ian Judson<sup>5</sup>; Angelo P. Dei Tos<sup>6</sup>; Paolo Verderio<sup>1</sup>; Paolo Casali<sup>1</sup>; Penella J. Wolf<sup>7</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; <sup>2</sup>European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; <sup>3</sup>University of Heidelberg, Heidelberg, Germany; <sup>4</sup>Leiden University Medical Centre, Leiden, Netherlands; <sup>5</sup>The Royal NHS Foundation Trust, London, United Kingdom; <sup>6</sup>Treviso General Hospital, Treviso, Italy; <sup>7</sup>University of Sheffield, Sheffield, United Kingdom

Paper 006 3042737  
**PROPENSITY SCORE MATCHING ANALYSIS OF DOXORUBICIN PLUS DACARBAZINE, DOXORUBICIN PLUS IFOSFAMIDE OR DOXORUBICIN ALONE AS FIRST-LINE TREATMENT FOR ADVANCED, METASTATIC OR UNRESECTABLE LEIOMYOSARCOMA: A RETROSPECTIVE STUDY FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP**  
**Lorenzo D'Ambrosio**<sup>1</sup>; Nathan Touati<sup>2</sup>; Jean-Yves Blay<sup>3</sup>; Tiziana Venesio<sup>4</sup>; Ronan Flippot<sup>17</sup>; Anna M. Czarnecka<sup>5</sup>; Sophie Piperno-Neumann<sup>6</sup>; Javier Martín-Broto<sup>7</sup>; Roberta Sanfilippo<sup>8</sup>; Daniela Katz<sup>9</sup>; Florence Duffaud<sup>10</sup>; Bruno Vincenzi<sup>11</sup>; Bernd Kasper<sup>12</sup>; Daniel P. Stark<sup>13</sup>; Filomena Mazzeo<sup>14</sup>; Armin Tuchscherer<sup>15</sup>; Saskia Litiere<sup>2</sup>; Ward Sents<sup>2</sup>; Silvia Stacchiotti<sup>8</sup>; Hans Gelderblom<sup>16</sup>; Alessandro Gronchi<sup>8</sup>  
<sup>1</sup>Department of Oncology, University of Torino, Torino, Italy; <sup>2</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; <sup>3</sup>University Claude Bernard Lyon I, Centre Leon Bernard, Lyon, France; <sup>4</sup>Medical Oncology - Sarcoma Unit, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>5</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; <sup>6</sup>Medical Oncology, Institute Curie, Paris, France; <sup>7</sup>Medical Oncology, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; <sup>8</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>9</sup>Assaf Harofeh Medical Center, Zrifin, Israel; <sup>10</sup>Service d'Oncologie Médicale Chu la Timone, Marseille, France; <sup>11</sup>University Campus Bio-Medico of Rome, Roma, Italy; <sup>12</sup>Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, ITM - Interdisciplinary Tumor Center Mannheim, Mannheim, Germany; <sup>13</sup>St James's Institute of Oncology, Leeds, United Kingdom; <sup>14</sup>Clinique Universitaire Saint-Luc, Institut Roi Albert II, Brussels, Belgium; <sup>15</sup>University Hospital Cologne, Köln, Germany; <sup>16</sup>Leiden University Medical Center, Leiden, Netherlands; <sup>17</sup>Gustave Roussy Cancer Center, Villejuif, France

- Paper 007 3042520  
**PHASE 1B STUDY OF OLARATUMAB PLUS DOXORUBICIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA: INITIAL RESULTS**  
**Sebastian Bauer**<sup>1</sup>; Neeta Somaiah<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Peter Reichardt<sup>4</sup>; Hector Soto Parra<sup>5</sup>; Rainer Hamacher<sup>1</sup>; Andrew Lithio<sup>6</sup>; Gary Mo<sup>6</sup>; Samuel Ramage<sup>6</sup>; Jonathan Trent<sup>7</sup>  
<sup>1</sup>West German Cancer Center, University of Duisburg-Essen, Essen, Germany; <sup>2</sup>MD Anderson Cancer Center, University of Texas, Houston, TX, USA; <sup>3</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>4</sup>Helios Klinikum Berlin-Buch, Berlin, Germany; <sup>5</sup>Department of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele, Catania, Italy; <sup>6</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>7</sup>Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
- Paper 008 3042717  
**ANTHRACYCLINE-BASED VERSUS GEMCITABINE-BASED ADJUVANT CHEMOTHERAPY IN FIGO STAGE 1 UTERINE LEIOMYOSARCOMA**  
**Roberta Sanfilippo**<sup>1</sup>; Rosanna Mancari<sup>2</sup>; Sara Manglaviti<sup>1</sup>; Giorgio Bogani<sup>1</sup>; Domenica Lorusso<sup>1</sup>; Elena Fumagalli<sup>1</sup>; Rossella Bertulli<sup>1</sup>; Angelo Paolo Dei Tos<sup>3</sup>; Paola Collini<sup>1</sup>; Francesco Raspagliesi<sup>1</sup>; Nicoletta Colombo<sup>2</sup>; Paolo Casali<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Gynaecology department, IEO, Milan, Italy; <sup>3</sup>General Hospital Treviso, Treviso, Italy
- Paper 009 3042702  
**EUROPEAN PHASE I/II TRASTS TRIAL OF TRABECTEDIN PLUS RADIOTHERAPY IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA (STS): A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY**  
Javier Martín-Broto<sup>1</sup>; Antonio Lopez-Pousa<sup>2</sup>; Nadia Hindi<sup>1</sup>; Josefina Cruz<sup>3</sup>; Javier Peinado<sup>1</sup>; Carlo Morosi<sup>4</sup>; **Josep Isern Verdun**<sup>2</sup>; Maria Carmen Dolado<sup>5</sup>; Rosa Maria Alvarez Alvarez<sup>5</sup>; Ana Alvarez González<sup>5</sup>; Tiziana Venesio<sup>6</sup>; Marco Gatti<sup>6</sup>; Pablo Luna Fra<sup>7</sup>; Ignacio Alastuey<sup>7</sup>; Jean-Yves Blay<sup>8</sup>; Marie-Pierre Sunyach<sup>8</sup>; Inmaculada Rincon<sup>10</sup>; Alessandro Gronchi<sup>4</sup>; Jesus Romero<sup>9</sup>  
<sup>1</sup>Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain; <sup>2</sup>Hospital Sant Pau, Barcelona, Spain; <sup>3</sup>University Hospital of Canary Islands, Santa Cruz De Tenerife, Spain; <sup>4</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>5</sup>University Hospital Gregorio Marañón, Madrid, Spain; <sup>6</sup>Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>7</sup>University Hospital Son Espases, Palma de Mallorca, Spain; <sup>8</sup>Centre Léon Bérard, Lyon, France; <sup>9</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>10</sup>University Hospital Virgen del Rocío, Seville, Spain

Discussion – Florence Duffaud

4:00 pm - 6:00 pm

– SESSION 3 –

Salon del Cavalieri 2,3,4

## GIST

Moderators: **Richard Riedel** and **Sebastian Bauer**

- Paper 010 3042567  
**MULTICENTRIC RETROSPECTIVE ANALYSIS OF PATIENTS WITH KIT EXON 9 MUTATED GIST**  
Almudena Callejo Goena<sup>1</sup>; Sara Faouzi<sup>2</sup>; Olivier Bouche<sup>3</sup>; Thomas Chevalier<sup>4</sup>; Nicolas Isambert<sup>5</sup>; Florence Duffaud<sup>4</sup>; Olivier Collard<sup>6</sup>; Nicolas Penel<sup>7</sup>; Olivier Mir<sup>2</sup>; Philippe Terrier<sup>3</sup>; **Jean-Yves Blay**<sup>9</sup>; Axel Le Cesne<sup>2</sup>  
<sup>1</sup>Medical Oncology, Cruces University Hospital, Barakaldo, Bizkaia, Spain; <sup>2</sup>Medical Oncology, Gustave Roussy Institute, Villejuif, France; <sup>3</sup>Digestive Oncology, Chu Robert Debre, Reims, France; <sup>4</sup>Medical Oncology, Chu La Timone and Aix Marseille Universite (Amu), Marseille, France; <sup>5</sup>Department of Early Clinical Trials, Centre Georges-François Leclerc, Dijon, France; <sup>6</sup>Medical Oncology, Institut De Cancerologie De La Loire – Lucien Neuwirth, La Loire, France; <sup>7</sup>Medical Oncology, Oscar Lambret Center, Lille, France; <sup>8</sup>Department Of Pathology, Gustave Roussy Institute, Villejuif, France; <sup>9</sup>Medical Oncology, Centre Leon Berard, Lyon, France

- Paper 011 3041313  
**A WEB-BASED SURVEY OF PERCEIVED COGNITIVE IMPAIRMENTS AND OTHER PATIENT-REPORTED OUTCOMES IN GIST PATIENTS**  
Robert Ferguson<sup>1</sup>; Jessica Manculich<sup>2</sup>; Hsuan Chang<sup>2</sup>; Beth Snitz<sup>3</sup>; Dana Bovbjerg<sup>4</sup>; **Anette Duensing**<sup>5</sup>  
<sup>1</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>2</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; <sup>3</sup>Dept. of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>4</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>5</sup>Cancer Therapeutics Program, UPMC Hillman Cancer Center, Dept. of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Paper 012 3027631  
**AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA**  
**Michael Heinrich**<sup>1</sup>; Margaret von Mehren<sup>2</sup>; Robin L. Jones<sup>3</sup>; Sebastian Bauer<sup>4</sup>; Yoon-Koo Kang<sup>5</sup>; Patrick Schöffski<sup>6</sup>; Ferry Eskens<sup>7</sup>; Cesar Serrano<sup>8</sup>; Philippe Cassier<sup>9</sup>; Olivier Mir<sup>10</sup>; William D. Tap<sup>11</sup>; Piotr Rutkowski<sup>12</sup>; Jonathan Trent<sup>13</sup>; Shreyaskumar Patel<sup>14</sup>; Sant P. Chawla<sup>15</sup>; Teresa Zhou<sup>16</sup>; Tamiaka Lauz<sup>16</sup>; Oleg Schmidt-Kittler<sup>16</sup>; Khalid K. Mamlouk<sup>16</sup>; Beni B. Wolf<sup>16</sup>; Suzanne George<sup>17</sup>  
<sup>1</sup>OHSU Knight Cancer Institute, Portland, OR, USA; <sup>2</sup>Fox Chase Cancer Centre, Philadelphia, PA, USA; <sup>3</sup>Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; <sup>4</sup>University of Duisburg-Essen, Essen, Germany; <sup>5</sup>Asan Medical Centre, Seoul, Korea (the Republic of); <sup>6</sup>University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; <sup>7</sup>Erasmus MC Cancer Institute, Rotterdam, Netherlands; <sup>8</sup>Vall d' Hebron Institute of Oncology, Barcelona, Spain; <sup>9</sup>Centre Léon Bérard, Lyon, France; <sup>10</sup>Institut Gustave Roussy; Edouard Vaillant Villejuif, Villejuif, France; <sup>11</sup>Memorial Sloan Kettering Cancer Centre, New York, NY, USA; <sup>12</sup>Maria Skłodowska-Curie Institute - Oncology Center, Warszawa, Poland; <sup>13</sup>Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; <sup>14</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>15</sup>Sarcoma Oncology Centre, Santa Monica, CA, USA; <sup>16</sup>Blueprint Medicines Corporation, Cambridge, MA, USA; <sup>17</sup>Dana Farber Cancer Institute, Boston, MA, USA
- Paper 013 3033840  
**INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFRINHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS**  
**Suzanne George**<sup>3</sup>; Michael Heinrich<sup>10</sup>; Ping Chi<sup>4</sup>; Albiruni Razak<sup>5</sup>; Margaret von Mehren<sup>6</sup>; Michael Gordon<sup>7</sup>; Kristen Ganjoo<sup>2</sup>; Neeta Somaiah<sup>8</sup>; Jonathan Trent<sup>11</sup>; Julie Wolf<sup>9</sup>; Rodrigo Ruiz-Soto<sup>1</sup>; Oliver Rosen<sup>1</sup>; Filip Janku<sup>8</sup>  
<sup>1</sup>Deciphera, Waltham, MA, USA; <sup>2</sup>Stanford University, Palo Alto, CA, USA; <sup>3</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>4</sup>MSKCC, New York, NY, USA; <sup>5</sup>Princess Margaret Cancer Centre, Toronto, ON, Canada; <sup>6</sup>Fox Chase Cancer Center, Philadelphia, PA, USA; <sup>7</sup>Pinnacle Oncology Hematology, Scottsdale, AZ, USA; <sup>8</sup>MDACC, Houston, TX, USA; <sup>9</sup>Biostats Consultants, Denver, CO, USA; <sup>10</sup>OHSU, Portland, OR, USA; <sup>11</sup>University Miami, Miami, FL, USA
- Discussion – Victor Villalobos
- Paper 014 3041747  
**NON-INVASIVE DETECTION OF CTDNA REVEALS INTRATUMOR HETEROGENEITY AND IS ASSOCIATED WITH TUMOR BURDEN IN GASTROINTESTINAL STROMAL TUMOR**  
**Boye Kjetil**<sup>1</sup>; Heidi Namløs<sup>2</sup>; Skyler J. Mishkin<sup>3</sup>; Tale Barøy<sup>2</sup>; Susanne Lorenz<sup>4</sup>; Bodil Bjerkehagen<sup>5</sup>; Eva Stratford<sup>2</sup>; Else Munthe<sup>2</sup>; Brian A. Kudlow<sup>3</sup>; Ola Myklebost<sup>2</sup>; Leonardo A. Meza-Zepeda<sup>2</sup>  
<sup>1</sup>Department of Oncology, Oslo University Hospital, Oslo, Norway; <sup>2</sup>Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; <sup>3</sup>Archer DX, Inc., Boulder, CO, USA; <sup>4</sup>Genomics Core Facility, Oslo University Hospital, Oslo, Norway; <sup>5</sup>Department of Pathology, Oslo University Hospital, Oslo, Norway

- Paper 015      3042824  
**UTILITY OF CIRCULATING TUMOR DNA (CTDNA) IN THE MANAGEMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST): ANALYSIS OF 184 PATIENTS**  
*Junaid Arshad<sup>1</sup>; Breelyn A. Wilky<sup>1</sup>; Ali Roberts<sup>2</sup>; Becky Nagy<sup>2</sup>; **Jonathan Trent<sup>1</sup>***  
<sup>1</sup>Sarcoma Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA;  
<sup>2</sup>Guardant Health, Redwood City, CA, USA
- Paper 016      3030004  
**CLINICAL VALUE OF CT-DNA IN LOCALIZED AND ADVANCED GIST: CROSS-VALIDATION OF AMPLICON-BASED NGS WITH DD-PCR IN MATCHED TISSUE AND PLASMA SAMPLES**  
**Cesar Serrano<sup>1</sup>**; Ana Vivancos<sup>5</sup>; Antonio Lopez-Pousa<sup>12</sup>; Judit Matito<sup>5</sup>; Francesco M. Mancuso<sup>5</sup>; Claudia Valverde<sup>11</sup>; Sergi Quiroga<sup>6</sup>; Stefania Landolfi<sup>2</sup>; Sandra Castro<sup>7</sup>; Cristina Dopazo<sup>7</sup>; Ana Sebio<sup>12</sup>; Anna C. Virgili Manrique<sup>12</sup>; Maria M Menso<sup>8</sup>; Javier Martín-Broto<sup>9</sup>; Alfonso Garcia-Valverde<sup>10</sup>; Jordi Rosell<sup>10</sup>; Jonathan A. Fletcher<sup>3</sup>; Suzanne George<sup>4</sup>; Joan Carles<sup>11</sup>; Joaquín Arribas<sup>10</sup>  
<sup>1</sup>Preclinical Research Program and Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO); Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain; <sup>2</sup>Pathology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>3</sup>Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; <sup>4</sup>Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>5</sup>Genomic Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; <sup>6</sup>Radiology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>7</sup>Surgical Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>8</sup>Radiology, Sant Pau Hospital, Barcelona, Spain; <sup>9</sup>Medical Oncology, Virgen del Rocío Hospital, Sevilla, Spain; <sup>10</sup>Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; <sup>11</sup>Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>12</sup>Medical Oncology, Sant Pau Hospital, Barcelona, Spain

Discussion – Bartosz Chmielowski

6:00 pm - 7:00 pm

**Poster Viewing Reception**

*Salon de Cavalieri 1 & Gallery*

|                   |                    |                                |
|-------------------|--------------------|--------------------------------|
| 6:00 am - 7:00 am | Registration       | Salon de Cavalieri 1 & Gallery |
| 7:00 am - 8:00 am | Coffee and Posters | Salon de Cavalieri 1 & Gallery |

8:00 am - 10:00 am

– SESSION 4 –

Salon del Cavalieri 2,3,4

### Soft Tissue Sarcoma: Targeted Therapy

Moderators: **Thierry Alcindor** and **Robin Jones**

Paper 017

3016595

#### **PROSPECTIVE TRIAL OF CRIZOTINIB (C) IN PATIENTS (PTS) WITH ADVANCED, INOPERABLE INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMFT) WITH AND WITHOUT ALK ALTERATIONS: EORTC PHASE II STUDY 90101 "CREATE"**

**Patrick Schöffski**<sup>1</sup>; Jozef Sufliarsky<sup>2</sup>; Hans Gelderblom<sup>3</sup>; Jean-Yves Blay<sup>7</sup>; Sandra Strauss<sup>8</sup>; Silvia Stacchiotti<sup>9</sup>; Piotr Rutkowski<sup>10</sup>; Lars Lindner<sup>11</sup>; Michael Leahy<sup>12</sup>; Antoine Italiano<sup>13</sup>; Maria Debiec-Rychter<sup>14</sup>; Raf Sciot<sup>4</sup>; Sandrine Marreaud<sup>5</sup>; Axelle Nzokirantevye<sup>5</sup>; Agnieszka Wozniak<sup>6</sup>  
<sup>1</sup>General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; <sup>2</sup>National Cancer Institute, Bratislava, Slovakia; <sup>3</sup>Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; <sup>4</sup>Department of Pathology, University Hospitals Leuven, Leuven, Belgium; <sup>5</sup>European Organisation for Research and Treatment of Cancer, Brussels, Belgium; <sup>6</sup>Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; <sup>7</sup>Université Cl. Bernard Lyon 1, Centre Léon Bérard, Lyon, France; <sup>8</sup>Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; <sup>9</sup>Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; <sup>10</sup>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland; <sup>11</sup>Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; <sup>12</sup>The Christie NHS Foundation Trust, Manchester, United Kingdom; <sup>13</sup>Institut Bergonié, Bordeaux, France; <sup>14</sup>Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium

Paper 018

3006132

#### **ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH *MET* ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"**

**Patrick Schöffski**<sup>1</sup>; **Agnieszka Wozniak**<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Piotr Rutkowski<sup>4</sup>; Jean-Yves Blay<sup>5</sup>; Lars Lindner<sup>8</sup>; Sandra Strauss<sup>9</sup>; Alan Anthoney<sup>12</sup>; Florence Duffaud<sup>14</sup>; Stephan Richter<sup>13</sup>; Raf Sciot<sup>6</sup>; Debiec-Rychter Maria<sup>10</sup>; Sandrine Marreaud<sup>7</sup>; Laurence Collette<sup>7</sup>; Sebastian Bauer<sup>11</sup>  
<sup>1</sup>General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; <sup>2</sup>Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; <sup>3</sup>Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; <sup>4</sup>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; <sup>5</sup>Université Claude Bernard Lyon Institute, Centre Léon Bérard, Lyon, France; <sup>6</sup>Department of Pathology, University Hospitals Leuven, Leuven, Belgium; <sup>7</sup>European Organisation for Research and Treatment of Cancer, Brussels, Belgium; <sup>8</sup>Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; <sup>9</sup>Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; <sup>10</sup>Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium; <sup>11</sup>Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany; <sup>12</sup>Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; <sup>13</sup>University Cancer Center/Medical Dept, University Hospital Carl Gustav Carus, Dresden, Germany; <sup>14</sup>Medical oncology Unit, La Timone University Hospital, Marseille, France

- Paper 019 3025592  
**MILADEMETAN, AN ORAL MDM2 INHIBITOR, IN WELL-DIFFERENTIATED/DE-DIFFERENTIATED LIPOSARCOMA: RESULTS FROM A PHASE 1 STUDY IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS**  
**Mrinal Gounder**<sup>1</sup>; Todd M. Bauer<sup>2</sup>; Gary K. Schwartz<sup>3</sup>; Amy M. Weise<sup>4</sup>; Patricia LoRusso<sup>5</sup>; Prasanna Kumar<sup>6</sup>; Shuquan Chen<sup>6</sup>; Jeanne Mendell<sup>6</sup>; Jarema Kochan<sup>6</sup>; Oleg Zernovak<sup>6</sup>; David S. Hong<sup>7</sup>  
<sup>1</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA; <sup>2</sup>Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA; <sup>3</sup>Columbia University Medical Center, New York, NY, USA; <sup>4</sup>Karmanos Cancer Institute, Detroit, MI, USA; <sup>5</sup>Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA; <sup>6</sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; <sup>7</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Paper 020 3042882  
**PHASE 2 STUDY OF THE CDK4 INHIBITOR ABEMACICLIB IN DEDIFFERENTIATED LIPOSARCOMA**  
**Mark A. Dickson**<sup>1</sup>; Sandra D'Angelo<sup>1</sup>; Mrinal Gounder<sup>1</sup>; Mary L. Keohan<sup>1</sup>; Ciara M. Kelly<sup>1</sup>; Ping Chi<sup>1</sup>; Cristina Antonsecu<sup>4</sup>; Jonathan Landa<sup>2</sup>; Li-Xuan Qin<sup>5</sup>; Andrew Koff<sup>6</sup>; Aimee M. Crago<sup>3</sup>; Sam Singer<sup>3</sup>; William D. Tap<sup>1</sup>  
<sup>1</sup>Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Radiology, Memorial Sloan Kettering, New York, NY, USA; <sup>3</sup>Surgery, Memorial Sloan Kettering, New York, NY, USA; <sup>4</sup>Pathology, Memorial Sloan Kettering, New York, NY, USA; <sup>5</sup>Biostatistics, Memorial Sloan Kettering, New York, NY, USA; <sup>6</sup>Molecular Biology, Sloan Kettering Institute, New York, NY, USA
- Discussion – Javier Martin-Broto
- Paper 021 3042818  
**PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA**  
Geraldine OSullivan Coyne<sup>1</sup>; Elad Sharon<sup>2</sup>; Nancy Moore<sup>1</sup>; Robert Meehan<sup>3</sup>; Naoko Takebe<sup>1</sup>; Lamin Juwara<sup>4</sup>; Laurence Rubinstein<sup>2</sup>; William Read<sup>5</sup>; Richard F. Riedel<sup>7</sup>; Priscilla Merriam<sup>8</sup>; James Hu<sup>6</sup>; Melissa Burgess<sup>9</sup>; James Doroshow<sup>1</sup>; **Alice Chen**<sup>1</sup>  
<sup>1</sup>Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; <sup>2</sup>Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; <sup>3</sup>Moderna Therapeutics, Cambridge, MA, USA; <sup>4</sup>National Cancer Institute, Bethesda, MD, USA; <sup>5</sup>Emory Cancer Center, Atlanta, GA, USA; <sup>6</sup>University of Southern California, Los Angeles, CA, USA; <sup>7</sup>Duke University School of Medicine, Durham, NC, USA; <sup>8</sup>Dana Farber Cancer Institute, Boston, MD, USA; <sup>9</sup>UPMC Hillman Cancer Center, Pittsburgh, PA, USA
- Paper 022 3033993  
**EZH2 INHIBITOR TAZEMETOSTAT (TAZ) INTERIM DATA IN ADULTS AND PEDIATRIC PATIENTS WITH INI1-NEGATIVE SOFT-TISSUE SARCOMAS (STS) INCLUDING EPITHELIOID SARCOMA (ES) (NCT02601950, NCT02601937)**  
**Mrinal Gounder**<sup>1</sup>; Patrick Schöffski<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Victor Villalobos<sup>4</sup>; Rashmi Chugh<sup>5</sup>; Mark Agulnik<sup>6</sup>; Steven Attia<sup>7</sup>; Tom Wei-Wu Chen<sup>8</sup>; Gupta Abha<sup>9</sup>; Thierry Jahan<sup>10</sup>; Robin Jones<sup>22</sup>; Antoine Italiano<sup>11</sup>; Jean-Yves Blay<sup>12</sup>; Gregory M. Cote<sup>13</sup>; George Demetri<sup>14</sup>; Elizabeth Loggers<sup>15</sup>; Ravin Ratan<sup>16</sup>; Maryam Fouladi<sup>17</sup>; Margaret Macy<sup>18</sup>; Guy Makin<sup>19</sup>; Alicia Clawson<sup>20</sup>; Scott Daigle<sup>20</sup>; Chelsea Mencio<sup>20</sup>; Inbal Sapir<sup>20</sup>; Franck Bourdeaut<sup>21</sup>  
<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; <sup>3</sup>Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>4</sup>University of Colorado, Denver, CO, USA; <sup>5</sup>Michigan Medicine Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>6</sup>Northwestern Memorial Hospital, Chicago, IL, USA; <sup>7</sup>Mayo Clinic in Florida, Jacksonville, FL, USA; <sup>8</sup>National Taiwan University Hospital, Taipei City, Japan; <sup>9</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>10</sup>University of California, San Francisco, CA, USA; <sup>11</sup>Institut Bergonie, Bordeaux, France; <sup>12</sup>Centre Léon Bérard, Lyon, France; <sup>13</sup>Massachusetts General Hospital, Boston, MA, USA; <sup>14</sup>Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; <sup>15</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>16</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>17</sup>Cincinnati Children's Hospital, Cincinnati, OH, USA; <sup>18</sup>Children's Hospital Colorado, Aurora, CO, USA; <sup>19</sup>University of Manchester, Manchester, United Kingdom; <sup>20</sup>Epizyme, Cambridge, MA, USA; <sup>21</sup>Curie Institute, Paris, France; <sup>22</sup>The Royal Marsden Hospital and Institute for Cancer Research, London, United Kingdom

Paper 023

3029169

**ACTIVITY OF LAROTRECTINIB IN SARCOMA PATIENTS WITH TRK FUSION CANCER**

**Noah Federman**<sup>1</sup>; Daniel Orbach<sup>2</sup>; Shivaani Kummar<sup>3</sup>; Alexander Drilon<sup>4</sup>; Ulrik Lassen<sup>5</sup>; Birgit Geoger<sup>6</sup>; Cornelis M. van Tillburg<sup>7</sup>; Theodore W. Laetsch<sup>8</sup>; Steven DuBois<sup>9</sup>; Ramamoorthy Nagasubramanian<sup>10</sup>; Neerav Shukla<sup>4</sup>; Michela Casanova<sup>11</sup>; Soledad Gallego<sup>12</sup>; Stefan Bielack<sup>13</sup>; Atrayee Basu-Mallick<sup>14</sup>; Mohamad Farid<sup>15</sup>; Jyoti Patel<sup>16</sup>; Vicki Keedy<sup>17</sup>; Scott Cruickshank<sup>18</sup>; Nora C. Ku<sup>18</sup>; Michael C. Cox<sup>18</sup>; Alberto Pappo<sup>19</sup>; George Demetri<sup>20</sup>; Douglas Hawkins<sup>21</sup>

<sup>1</sup>Departments of Pediatrics and Orthopaedics, Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA, USA; <sup>2</sup>SIREDO Oncology Center, Institut Curie, PSL University, Paris, France; <sup>3</sup>Stanford Cancer Center, Palo Alto, CA, USA; <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>5</sup>Rigshospitalet, Copenhagen, Denmark; <sup>6</sup>Gustave Roussy Cancer Center, Villejuif, France; <sup>7</sup>Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>8</sup>University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA; <sup>9</sup>Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA; <sup>10</sup>Nemours Children's Hospital, Orlando, FL, USA; <sup>11</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; <sup>12</sup>Hospital Universitario Vall d'Hebron, Barcelona, Spain; <sup>13</sup>Olgahospital, Klinikum Stuttgart, Stuttgart, Germany; <sup>14</sup>Thomas Jefferson University, Philadelphia, PA, USA; <sup>15</sup>National Cancer Centre, Singapore, Singapore; <sup>16</sup>University of Chicago, Chicago, IL, USA; <sup>17</sup>Vanderbilt University School of Medicine, Nashville, TN, USA; <sup>18</sup>Loxo Oncology Inc., South San Francisco, CA, USA; <sup>19</sup>St Jude Children's Research Hospital, Memphis, TN, USA; <sup>20</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; <sup>21</sup>Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Discussion – Neeta Somaiah

10:00 am - 10:30 am

**Morning Coffee Break**

Salon de Cavalieri 1 & Gallery

10:30 am - 11:00 am

**Presentation of Young Investigator Awards**

Salon de Cavalieri 1 & Gallery

Paper 036

3035962

**SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS**

**Jessica Gartrell**; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat  
St. Jude Children's Research Hospital, Memphis, TN, USA

Paper 021

3042818

**PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA**

Geraldine OSullivan Coyne<sup>1</sup>; Elad Sharon<sup>2</sup>; Nancy Moore<sup>1</sup>; Robert Meehan<sup>3</sup>; Naoko Takebe<sup>1</sup>; Lamin Juwara<sup>4</sup>; Laurence Rubinstein<sup>2</sup>; William Read<sup>5</sup>; Richard F. Riedel<sup>7</sup>; Priscilla Merriam<sup>8</sup>; James Hu<sup>6</sup>; Melissa Burgess<sup>9</sup>; James Doroshow<sup>1</sup>; **Alice Chen**<sup>1</sup>

<sup>1</sup>Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; <sup>2</sup>Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; <sup>3</sup>Moderna Therapeutics, Cambridge, MA, USA; <sup>4</sup>National Cancer Institute, Bethesda, MD, USA; <sup>5</sup>Emory Cancer Center, Atlanta, GA, USA; <sup>6</sup>University of Southern California, Los Angeles, CA, USA; <sup>7</sup>Duke University School of Medicine, Durham, NC, USA; <sup>8</sup>Dana Farber Cancer Institute, Boston, MD, USA; <sup>9</sup>UPMC Hillman Cancer Center, Pittsburgh, PA, USA

11:00 am - 12:00 pm

– HERMAN SUIT LECTURE –

Salon del Cavaliere 1 & Gallery

**How Molecular Discoveries Changed our Morphology-Based Profession**  
**Cristina Antonescu**

(Memorial Sloan Kettering Cancer Center, New York, NY)

12:00 pm - 1:30 pm

Lunch

Belle Arti & Garden Lobby

1:30 pm - 3:30 pm

– SESSION 5 –

Salon del Cavaliere 2,3,4

**Benign and Intermediate Grade Bone/Soft Tissue Lesions**

Moderators: **William Tseng** and **Katherine Thornton**

Paper 024

3042858

**RISK FACTORS IN TENOSYNOVIAL GIANT CELL TUMOURS OF LARGE JOINTS, EVALUATED IN 30 INTERNATIONAL SARCOMA CENTERS**

**Monique Mastboom**; Emanuela Palmerini; Floortje Verspoor; Anja Rueten-Budde; Silvia Stacchiotti; Eric Staals; Gerard Schaap; Paul Jutte; Will Aston; Andreas Leithner; Dietmar Dammerer; Akihiko Takeuchi; Quirina Thio; Xiaohui Niu; Jay Wunder; Michiel A. van de Sande  
Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands

Paper 025

3038487

**POSITIVE ASSOCIATION BETWEEN TUMOR RESPONSE AND PATIENT-REPORTED OUTCOMES IN PHASE 3 ENLIVEN STUDY OF PEXIDARTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT)**

Heather L. Gelhorn<sup>1</sup>; Charles Peterfy<sup>2</sup>; Xin Ye<sup>3</sup>; **Rebecca M. Speck**<sup>1</sup>; Emanuela Palmerini<sup>4</sup>; Silvia Stacchiotti<sup>5</sup>; Jayesh Desai<sup>6</sup>; Andrew Wagner<sup>7</sup>; Thierry Alcindor<sup>8</sup>; Kristen Ganjoo<sup>9</sup>; Javier Martín-Broto<sup>10</sup>; Christopher Ryan<sup>11</sup>; Qiang Wang<sup>3</sup>; Dale Shuster<sup>3</sup>; William D. Tap<sup>12</sup>; Hans Gelderblom<sup>13</sup>  
<sup>1</sup>Evidera, Bethesda, MD, USA; <sup>2</sup>Spire Sciences, Inc., Boca Raton, FL, USA; <sup>3</sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; <sup>4</sup>Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>6</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; <sup>7</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>8</sup>McGill University, Montreal, QC, Canada; <sup>9</sup>Stanford Cancer Institute, Stanford, CA, USA; <sup>10</sup>Hospital Universitario Virgen del Rocío, Seville, Spain; <sup>11</sup>Oregon Health & Science University, Portland, OR, USA; <sup>12</sup>Memorial Sloan Kettering Cancer Institute, New York, NY, USA; <sup>13</sup>Leiden University Medical Center, Leiden, Netherlands

Paper 026

3042414

**PRIMARY VASCULAR TUMORS OF BONE: AN ANALYSIS OF 427 PATIENTS**

**Marta Sbaraglia**<sup>1</sup>; Alberto Righi<sup>2</sup>; Marco Gambarotti<sup>2</sup>; Dino Gibertoni<sup>3</sup>; Stefania Benini<sup>2</sup>; Piero Picci<sup>2</sup>; Angelo Paolo Dei Tos<sup>1</sup>  
<sup>1</sup>University of Padua, Treviso, Italy; <sup>2</sup>Pathology, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy; <sup>3</sup>Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

Paper 027 3042427  
**PHASE II TRIAL OF PAZOPANIB IN ADVANCED EXTRASKELETAL MYXOID CHONDROSARCOMA. A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY**  
**Silvia Stacchiotti**<sup>1</sup>; Stefano Ferrari<sup>2</sup>; Antonio Redondo<sup>3</sup>; Emanuela Palmerini<sup>2</sup>; Nadia Hindi<sup>4</sup>; Maria A. Vaz<sup>5</sup>; Anna Maria Frezza<sup>1</sup>; Antonio Gutierrez<sup>6</sup>; Antonio Lopez-Pousa<sup>16</sup>; Tiziana Venesio<sup>7</sup>; Antoine Italiano<sup>8</sup>; Sarah N. Dumont<sup>9</sup>; Jean-Yves Blay<sup>10</sup>; Nicolas Penel<sup>11</sup>; Daniel Bernabeu<sup>12</sup>; Enrique De Alava<sup>13</sup>; Dominique Ranchere-Vince<sup>10</sup>; Gian Paolo Dagrada<sup>1</sup>; Paola Collini<sup>1</sup>; Josefina Cruz<sup>14</sup>; Javier Martín-Broto<sup>15</sup>  
<sup>1</sup>Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>2</sup>Cancer Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>3</sup>Cancer Medicine, La Paz Institute for Health Research, Madrid, Spain; <sup>4</sup>University Hospital Virgen del Rocío, Sevilla, Spain; <sup>5</sup>Hospital Universitario Ramón y Cajal, Cajal, Spain; <sup>6</sup>Hospital Universitari Son Espases, Palma, Spain; <sup>7</sup>Cancer Medicine, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>8</sup>Institut Bergonie, Bordeaux, France; <sup>9</sup>Cancer Medicine, Goussavy, Lille, France; <sup>10</sup>Centre Léon Bérard, Lyon, France; <sup>11</sup>Centre Oscar Lambret, Lille, France; <sup>12</sup>Radiology, University Hospital La Paz, Madrid, France; <sup>13</sup>Institute of Biomedicine of Sevilla, Sevilla, Spain; <sup>14</sup>University Hospital of Canarias, Tenerife, Spain; <sup>15</sup>Sant Pau Hospital, Barcelona, Spain

Discussion – Paolo Casali

Paper 028 3042598  
**LONGITUDINAL DISTRESS ASSESSMENT AND RESPONSE TOOL (DART) SCREENING IN ADULTS WITH AGGRESSIVE FIBROMATOSIS: HIGH PREVALENCE OF PERSISTENT EMOTIONAL DISTRESS**  
**Abha Gupta**<sup>1</sup>; Nicole Byers<sup>1</sup>; Sally Burtenshaw<sup>2</sup>; Katrina Ingle<sup>2</sup>; Carol Swallow<sup>2</sup>; Savtaj Brar<sup>2</sup>; Anthony M. Griffin<sup>2</sup>; Peter Ferguson<sup>2</sup>; Jay Wunder<sup>2</sup>; Albiruni Razak<sup>1</sup>; Rebecca Gladdy<sup>2</sup>; Roberta Klein<sup>3</sup>; Madeline Li<sup>3</sup>  
<sup>1</sup>Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada; <sup>2</sup>Surgery, Mount Sinai Hospital, Toronto, ON, Canada; <sup>3</sup>Psychiatry, Princess Margaret Cancer Center, Toronto, ON, Canada

Paper 029 3042617  
**CAN WAIT AND SEE BE THE STANDARD OF CARE FOR INITIAL APPROACH TO PRIMARY SPORADIC DESMOID TUMORS? PRELIMINARY DATA FROM AN ITALIAN SARCOMA GROUP PROSPECTIVE STUDY**  
**Chiara Colombo**<sup>1</sup>; Marco Fiore<sup>1</sup>; Tiziana Venesio<sup>2</sup>; Erica Palesandro<sup>2</sup>; Paola Boccone<sup>2</sup>; Lorenzo D'Ambrosio<sup>2</sup>; Alba Bianco<sup>1</sup>; Paola Collini<sup>1</sup>; Elena Palassini<sup>1</sup>; Silvia Stacchiotti<sup>1</sup>; Angelo Paolo Dei Tos<sup>3</sup>; Paolo Casali<sup>1</sup>; Federica Perrone<sup>1</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; <sup>2</sup>IRCCS Istituto Candiolo, Torino, Italy; <sup>3</sup>Ospedale di Treviso, Treviso, Italy

Paper 030 3042719  
**INCORPORATION OF CTNNB1 MUTATION STATUS INTO A PRE-OPERATIVE DESMOID LOCAL RECURRENCE NOMOGRAM IMPROVES PREDICTIVE VALUE**  
**Iris Wei**<sup>1</sup>; Anthony Villano<sup>1</sup>; Andrea Knezevic<sup>2</sup>; Bhumika Jadeja<sup>1</sup>; Li-Xuan Qin<sup>2</sup>; Meera Hameed<sup>3</sup>; Sam Singer<sup>1</sup>; **Aimee M. Crago**<sup>1</sup>  
<sup>1</sup>Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Discussion – Bernd Kasper

3:30 pm - 4:00 pm

**Afternoon Coffee Break**

Salon de Cavalieri 1 & Gallery

**Ewing Sarcoma**

Moderators: **Abha Gupta** and **Piero Picci**

- Paper 031 3027408  
**EASY-TO-USE PRACTICAL CLINICAL TOOL FOR SURVIVAL ESTIMATION IN EWING SARCOMA AT DIAGNOSIS AND AFTER SURGERY**  
**Sarah E. Bosma**<sup>1</sup>; Carlo Lancia<sup>2</sup>; Anja J. Rüten-Budde<sup>2</sup>; Andreas Ranft<sup>3</sup>; Hans Gelderblom<sup>4</sup>; Marta Fiocco<sup>2</sup>; Michiel A. van de Sande<sup>1</sup>; Sander Dijkstra<sup>1</sup>; Uta Dirksen<sup>3</sup>  
<sup>1</sup>Orthopedics, Leiden University Medical Center, Leiden, Netherlands; <sup>2</sup>Mathematical Institute, Leiden University, Leiden, Netherlands; <sup>3</sup>Pediatrics III, University Hospital Essen, University Duisburg-Essen, Sarcoma Center, West German Cancer Center, Essen, Germany; <sup>4</sup>Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
- Paper 032 3042243  
**RETROSPECTIVE ANALYSIS OF USE OF WHOLE LUNG IRRADIATION FOR PATIENTS WITH NEWLY DIAGNOSED EWING SARCOMA AND PULMONARY METASTASES**  
Hadeel Halalshah<sup>1</sup>; Sue Kaste<sup>2</sup>; Matthew J. Krasin<sup>3</sup>; April Sykes<sup>4</sup>; Natasha Sahr<sup>4</sup>; Sheri Spunt<sup>5</sup>; Sara Federico<sup>1</sup>; Alberto Pappo<sup>1</sup>; **Michael W. Bishop**<sup>1</sup>  
<sup>1</sup>Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>2</sup>Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>3</sup>Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>4</sup>Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>5</sup>Pediatrics - Hematology/Oncology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, USA
- Paper 033 3042780  
**WHOLE-LUNG IRRADIATION AFTER HIGH-DOSE BUSULFAN/MELPHALAN CONDITIONING THERAPY IN EWING SARCOMA WITH LUNG METASTASES: A MULTICENTRIC STUDY**  
**Massimo E. Abate**<sup>1</sup>; Letizia Ronchi<sup>2</sup>; Barbara Diletto<sup>14</sup>; Lorenza Gandola<sup>14</sup>; Nadia Puma<sup>15</sup>; Angela Tamburini<sup>3</sup>; Maurizio Mascarin<sup>4</sup>; Elisa Coassin<sup>4</sup>; Arcangelo Prete<sup>5</sup>; Sebastian Asaftei<sup>6</sup>; Carla Manzitti<sup>7</sup>; Luca Coccoli<sup>8</sup>; Mariella Capasso<sup>9</sup>; Tiziana Venesio<sup>13</sup>; Emilia Pecori<sup>14</sup>; Marta Pierobon<sup>16</sup>; Anna Paioli<sup>1</sup>; Elisa Carretta<sup>10</sup>; Giovanni Piero Frezza<sup>11</sup>; Alessio Giuseppe Morganti<sup>2</sup>; Stefano Ferrari<sup>1</sup>; Piero Picci<sup>12</sup>; Alessandra Longhi<sup>1</sup>; Silvia Cammelli<sup>2</sup>; Roberto Luksch<sup>15</sup>  
<sup>1</sup>Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>2</sup>Radiotherapy, Sant'Orsola Hospital, Bologna, Italy; <sup>3</sup>Pediatric Oncoematology, Hospital Meyer, Firenze, Italy; <sup>4</sup>Radiotherapy, CRO Aviano, Aviano, Italy; <sup>5</sup>Pediatric Oncoematology, Sant'Orsola Hospital, Bologna, Italy; <sup>6</sup>Pediatric Oncoematology, OIRM Sant'ANNA, Torino, Italy; <sup>7</sup>Pediatric Oncology, Gaslini Hospital, Genova, Italy; <sup>8</sup>Pediatric Oncoematology, AOUP Pisa, Pisa, Italy; <sup>9</sup>Pediatric Oncology, AORN Santobono-Pausillipon, Napoli, Italy; <sup>10</sup>Statistics, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>11</sup>Radiotherapy, AUSL Bologna, Bologna, Italy; <sup>12</sup>Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>13</sup>Medical Oncology, Istituto Candiolo, Torino, Italy; <sup>14</sup>Radiotherapy, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Milano, Italy; <sup>15</sup>Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; <sup>16</sup>Pediatric Oncoematology, Azienda Ospedaliera di Padova, Padova, Italy
- Discussion – Rick Haas
- Paper 034 3042627  
**THE WNT-DEPENDENT SECRETOME ALTERS TUMOR: TUMOR MICROENVIRONMENT CROSSTALK TO PROMOTE INVASION AND ANGIOGENESIS IN EWING SARCOMA**  
Allegra Hawkins; Elisabeth Pedersen; Sonja Konzen; Colin Sperring; Sydney Treichel; **Elizabeth Lawlor**  
University of Michigan, Ann Arbor, MI, USA

- Paper 035 3042245  
**A PHASE I STUDY OF THE POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITOR, NIRAPARIB (NIR), IN COMBINAITON WITH IRINOTECAN (IRN) IN PATIENTS WITH ADVANCED EWING SARCOMA: RESULTS OF SARCO25 ARM 2**  
**Sandra J. Strauss**<sup>1</sup>; Karla V Ballman<sup>2</sup>; Kam Zaki<sup>1</sup>; Lee Helman<sup>3</sup>; Brigitte Widemann<sup>4</sup>; Douglas Hawkins<sup>5</sup>; Leo Mascarenhas<sup>3</sup>; J.W Glod<sup>4</sup>; Jay Ji<sup>6</sup>; Ziping Zhang<sup>6</sup>; Birgit Geoerger<sup>7</sup>; Jeremy Whelan<sup>1</sup>; Denise Reinke<sup>8</sup>; Shreyaskumar Patel<sup>9</sup>; Rashmi Chugh<sup>10</sup>  
<sup>1</sup>University College London Hospitals NHS Trust, London, United Kingdom; <sup>2</sup>Weill Cornell Medicine, New York, NY, USA; <sup>3</sup>Children's Center for Cancer and Blood Diseases, Los Angeles, CA, USA; <sup>4</sup>National Cancer Institute Centre for Cancer Research, Bethesda, MD, USA; <sup>5</sup>Seattle Children's Hospital, Seattle, OR, USA; <sup>6</sup>National Clinical Target Validation Laboratory, Bethesda, MD, USA; <sup>7</sup>Institut Gustave Roussy, Paris, France; <sup>8</sup>SARC, Ann Arbor, MI, USA; <sup>9</sup>MD Anderson, Houston, TX, USA; <sup>10</sup>University of Michigan, Ann Arbor, MI, USA
- Paper 036 3035962  
**SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS**  
**Jessica Gartrell**; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat  
St. Jude Children's Research Hospital, Memphis, TN, USA
- Paper 037 3027426  
**INNOVATIVE TARGETED THERAPY FOR EWING SARCOMA**  
**Shunya Ohmura**<sup>1</sup>; Martin F. Orth<sup>1</sup>; Aruna Marchetto<sup>1</sup>; Stefanie Stein<sup>1</sup>; Julia S. Gerke<sup>1</sup>; Giuseppina Sannino<sup>1</sup>; Julian Musa<sup>1</sup>; Fabienne Wehweck<sup>1</sup>; Maximilian M. Knott<sup>1</sup>; Jing Li<sup>1</sup>; Tilman Hölting<sup>1</sup>; Laura Romero-Pérez<sup>1</sup>; Florencia Cidre-Aranaz<sup>1</sup>; Horacio Bach<sup>2</sup>; Wolfgang Hartmann<sup>3</sup>; Uta Dirksen<sup>4</sup>; Thomas Kirchner<sup>5</sup>; Thomas G. Grünewald<sup>6</sup>  
<sup>1</sup>Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; <sup>2</sup>Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>Gerhard-Domagk Institute of Pathology, University Hospital of Muenster, Muenster, Germany; <sup>4</sup>Division of Hematology and Oncology, Department of Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany; <sup>5</sup>Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; <sup>6</sup>Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany

Discussion – Stephen Lessnick

7:00 pm - 10:00 pm

**Gala – Reception and Dinner at the beautiful Villa Miani  
next door to the Cavalieri Hotel. Cocktail Attire**

*Villa Miani*

**Circulating Tumor DNA** – Brian Crompton

- Poster 127 3042631  
**PILOT STUDY EVALUATING THE CONCORDANCE OF CIRCULATING TUMOR DNA ALTERATIONS WITH TUMOR-BASED SEQUENCING IN SOFT TISSUE SARCOMA**  
Bryce Demoret<sup>1</sup>; Sherri Z. Millis<sup>2</sup>; Gabriel Tinoco<sup>1</sup>; David Liebner<sup>1</sup>; **James L. Chen**<sup>1</sup>  
<sup>1</sup>The Ohio State University, Columbus, OH, USA; <sup>2</sup>Foundation Medicine, Cambridge, MA, USA
- Poster 128 3042674  
**CIRCSARC; NON-INVASIVE MONITORING OF SARCOMAS PATIENTS BY CIRCULATING TUMOUR DNA IN PLASMA**  
Heidi M. Namløs<sup>1</sup>; Seyed Hossein Moosavi<sup>1</sup>; Bodil Bjerkehagen<sup>2</sup>; Olga Zaikova<sup>3</sup>; Susanne Lorenz<sup>4</sup>; Lars Aasheim<sup>4</sup>; Eivind Hovig<sup>1</sup>; Nina L. Jebsen<sup>5</sup>; Ola Myklebost<sup>6</sup>; Boye Kjetil<sup>7</sup>; **Leonardo A. Meza-Zepeda**<sup>1</sup>  
<sup>1</sup>Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; <sup>2</sup>Department of Pathology, Oslo University Hospital, Oslo, Norway; <sup>3</sup>Department of Surgery, Oslo University Hospital, Oslo, Norway; <sup>4</sup>Department of Core Facilities, Oslo University Hospital, Oslo, Norway; <sup>5</sup>Department of Oncology, Haukeland University Hospital, Bergen, Norway; <sup>6</sup>Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>7</sup>Department of Oncology, Oslo University Hospital, Oslo, Norway
- Poster 129 3042933  
**ULTRA-SENSITIVE DETECTION OF TRANSLOCATIONS IN THE CELL-FREE DNA OF PEDIATRIC SARCOMA PATIENTS**  
**Avanthi T. Shah**<sup>1</sup>; Tej Azad<sup>2</sup>; Jake Chabon<sup>3</sup>; Stan Leung<sup>1</sup>; Aviv Spillinger<sup>1</sup>; Heng-Yi Liu<sup>1</sup>; Marcus Breese<sup>1</sup>; Maximilian Diehn<sup>3</sup>; Ash A. Alizadeh<sup>3</sup>; Alejandro Sweet-Cordero<sup>1</sup>  
<sup>1</sup>Pediatrics, UCSF, San Francisco, CA, USA; <sup>2</sup>Stanford University School of Medicine, Stanford, CA, USA; <sup>3</sup>Stanford Cancer Institute, Stanford, CA, USA
- Poster 130 3043078  
**NONINVASIVE MOLECULAR PROFILING AND RESPONSE MONITORING BY CELL-FREE DNA ANALYSIS IN OSTEOSARCOMA**  
**Emily Slotkin**<sup>1</sup>; Julie Yang<sup>2</sup>; Dana Tsui<sup>2</sup>  
<sup>1</sup>Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Poster 132 3042854  
**TREATMENT MONITORING IN PATIENTS WITH PEDIATRIC SARCOMAS USING CIRCULATING TUMOR DNA ANALYSIS: A FEASIBILITY STUDY**  
**Jun Zhao**<sup>1</sup>; Braden McDonald<sup>2</sup>; Tania Contente-Cuomo<sup>2</sup>; Ahuva Odenheimer<sup>2</sup>; Michelina de la Maza<sup>1</sup>; Pooja Hingorani<sup>1</sup>; Muhammed Murtaza<sup>2</sup>  
<sup>1</sup>Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, AZ, USA; <sup>2</sup>Center for Non-invasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA

**Geonomics** – Roberta Maestro

- Poster 182      3042599  
**DISCOVERY AND CHARACTERIZATION OF RECURRENT, TARGETABLE ALK FUSIONS IN LEIOMYOSARCOMA**  
**Lara E. Davis**<sup>1</sup>; Kevin Nusser<sup>1</sup>; Joanna Przybyl<sup>2</sup>; Janet Pittsenbarger<sup>1</sup>; Nicolle Hofmann<sup>1</sup>; Sushama Varma<sup>2</sup>; Sujay Vennam<sup>2</sup>; Maria Debiec-Rychter<sup>3</sup>; Matt van de Rijn<sup>2</sup>; Monika Davare<sup>1</sup>  
<sup>1</sup>Oregon Health & Science University, Portland, OR, USA; <sup>2</sup>Stanford University, Stanford, CA, USA; <sup>3</sup>KU Leuven, Leuven, Belgium
- Poster 183      3014793  
**GENOME INFORMED THERAPY FOR OSTEOSARCOMA**  
Leanne Sayles<sup>1</sup>; Marcus Breese<sup>1</sup>; Amanda Koehne<sup>1</sup>; Stan Leung<sup>1</sup>; Avanthi T. Shah<sup>1</sup>; Sheri Spunt<sup>2</sup>; Steven DuBois<sup>4</sup>; Douglas Hawkins<sup>3</sup>; **Alejandro Sweet-Cordero**<sup>1</sup>  
<sup>1</sup>Pediatrics, University of California San Francisco, San Francisco, CA, USA; <sup>2</sup>Pediatrics, Stanford University, San Francisco, CA, USA; <sup>3</sup>Pediatrics, University of Washington, Seattle, WA, USA; <sup>4</sup>Pediatrics, Dana Farber Cancer Institute, Boston, MA, USA
- Poster 185      3042669  
**COMPREHENSIVE GENOMIC PROFILING OF SYNOVIAL SARCOMAS IDENTIFIES GENOMICALLY DEFINED SUBGROUPS WITH CHARACTERISTIC ALTERATION PATTERNS**  
**Sherri Z. Millis**<sup>1</sup>; Peter Vorenkamp<sup>3</sup>; Petra Vorenkamp<sup>3</sup>; Jeffrey Ross<sup>1</sup>; Siraj Ali<sup>1</sup>; Sally Trabucco<sup>1</sup>; James L. Chen<sup>2</sup>  
<sup>1</sup>Foundation Medicine, Inc., Phoenix, AZ, USA; <sup>2</sup>The Ohio State University, Columbus, OH, USA; <sup>3</sup>Live For Others Foundation, Laguna Beach, CA, USA
- Poster 186      3042566  
**THE FUSION LANDSCAPE AND ACTIONABLE ALTERATIONS OF SARCOMA REVEALED BY “REAL WORLD” GENOMIC SEQUENCING**  
**Jason Roszik**<sup>1</sup>; Anthony P. Conley<sup>1</sup>; Roman Groisberg<sup>1</sup>; Roberto Carmagnani Pestana<sup>1</sup>; Shiraj Sen<sup>1</sup>; Vivek Subbiah<sup>1</sup>  
<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Poster 188      3042711  
**UTILITY OF FOUNDATION ONE HEME PROFILING IN SARCOMA: INSTITUTIONAL EXPERIENCE AND CLINICAL OUTCOMES**  
**Adrienne Victor**<sup>1</sup>; Deepak Sahasrabudhe<sup>1</sup>; Megan Baumgart<sup>1</sup>  
<sup>1</sup>Medical Oncology, University of Rochester, Rochester, NY, USA

**Immunotherapy** – Sandra D'Angelo

- Poster 216      3014823  
**NEOADJUVANT THERAPY INDUCES A POTENT INFLAMMATORY AND CORRESPONDING REGULATORY RESPONSE WITHIN THE SARCOMA IMMUNE MICROENVIRONMENT**  
**Teresa Kim**<sup>1</sup>; Matthew Spraker<sup>3</sup>; Y. David Seo<sup>1</sup>; Kimberly Smythe<sup>2</sup>; Robert Pierce<sup>2</sup>; Taylor Hain<sup>2</sup>; Edward Y. Kim<sup>3</sup>; Gabrielle Kane<sup>3</sup>; Isaac Jenkins<sup>5</sup>; Qianchuan (Chad) He<sup>4</sup>; Seth Pollack<sup>2</sup>  
<sup>1</sup>Surgery, University of Washington, Seattle, WA, USA; <sup>2</sup>Clinical Research Division, Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>3</sup>Radiation Oncology, University of Washington, Seattle, WA, USA; <sup>4</sup>Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>5</sup>Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

- Poster 229 3042851  
**RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY**  
**Sant P. Chawla**<sup>1</sup>; Seth Pollack<sup>2</sup>; Matthew Block<sup>7</sup>; Mihaela Druta<sup>3</sup>; Khanh Do<sup>4</sup>; John C. Morris<sup>5</sup>; Joseph W. Kim<sup>6</sup>; Chet Bohac<sup>8</sup>; Hailing Lu<sup>9</sup>; Sacha Gnjatic<sup>10</sup>; Robin L. Jones<sup>11</sup>; P. Hwu<sup>12</sup>; Neeta Somaiah<sup>13</sup>  
<sup>1</sup>Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; <sup>2</sup>Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; <sup>3</sup>Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; <sup>4</sup>Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; <sup>5</sup>Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; <sup>6</sup>Medical Oncology, Yale University, New Haven, CT, USA; <sup>7</sup>Medical Oncology, Mayo clinic, Rochester, MN, USA; <sup>8</sup>Clinical Development, Immune Design, South San Francisco, CA, USA; <sup>9</sup>Science, Immune Design, Seattle, WA, USA; <sup>10</sup>Immunology, Mt. Sinai, New York City, NY, USA; <sup>11</sup>Medical Oncology, Royal Marsden, London, United Kingdom; <sup>12</sup>Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>13</sup>Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
- Poster 230 3042145  
**IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY**  
**Sant P. Chawla**<sup>1</sup>; **Seth Pollack**<sup>2</sup>; Matthew Block<sup>11</sup>; Mihaela Druta<sup>3</sup>; Khanh Do<sup>4</sup>; John C. Morris<sup>5</sup>; Joseph W. Kim<sup>6</sup>; Chet Bohac<sup>7</sup>; Hailing Lu<sup>7</sup>; Sacha Gnjatic<sup>8</sup>; R. L. Jones<sup>9</sup>; P. Hwu<sup>10</sup>; Neeta Somaiah<sup>10</sup>  
<sup>1</sup>Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; <sup>2</sup>Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; <sup>3</sup>Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; <sup>4</sup>Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; <sup>5</sup>Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; <sup>6</sup>Medical Oncology, Yale University, New Haven, CT, USA; <sup>7</sup>Science, Immune Design, Seattle, WA, USA; <sup>8</sup>Immunology, Mt. Sinai, New York City, NY, USA; <sup>9</sup>Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; <sup>10</sup>Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>11</sup>Medical Oncology, Mayo Clinic, Rochester, MN, USA
- Poster 238 3042673  
**ACTIVITY OF TREMELIMUMAB AND DURVALUMAB IN ADVANCED SARCOMAS: PRELIMINARY RESULTS OF A SIGNAL-SEEKING PHASE 2 TRIAL**  
**Maya Kansara**<sup>1</sup>; Subotheni Thavaneswaran<sup>1</sup>; John Grady<sup>1</sup>; Mark Cowley<sup>1</sup>; Audrey Silvestri<sup>1</sup>; Mandy L. Ballinger<sup>1</sup>; Elektra Hajdu<sup>1</sup>; Emily Collignon<sup>1</sup>; Lucille Sebastian<sup>2</sup>; Katrin Sjoquist<sup>2</sup>; Wendy Hague<sup>2</sup>; Amy Prawira<sup>1</sup>; Anthony Joshua<sup>1</sup>; Charles Bailey<sup>3</sup>; Ulf Schmitz<sup>3</sup>; Trevor Pugh<sup>4</sup>; Torsten O. Nielsen<sup>5</sup>; Amanda R. Dancsok<sup>5</sup>; Chee Lee<sup>2</sup>; John Simes<sup>3</sup>; David M. Thomas<sup>1</sup>  
<sup>1</sup>Cancer Genomic Medicine, Garvan Institute, Sydney, NSW, Australia; <sup>2</sup>NHMRC Clinical Trials Centre, Sydney, NSW, Australia; <sup>3</sup>Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, NSW, Australia; <sup>4</sup>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; <sup>5</sup>Vancouver Coastal Health Research Institute and Faculty of Medicine, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
- Poster 240 3042810  
**INTERFERON GAMMA MAKES "COLD" SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA "HOT": RESULTS OF A PHASE 0 TRIAL**  
Shihong Zhang<sup>1</sup>; Venu Pillarisetty<sup>2</sup>; Lee D. Cranmer<sup>1</sup>; Stanley Riddell<sup>1</sup>; R. L. Jones<sup>3</sup>; **Seth Pollack**<sup>1</sup>  
<sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>2</sup>Surgery, University of Washington, Seattle, WA, USA; <sup>3</sup>Royal Marsden Hospital, London, United Kingdom

**Vascular Tumors** – Silvia Stacchiotti

- Poster 002 3042315  
**PITFALLS IN ANGIOSARCOMA DIAGNOSIS: LESSONS LEARNED FROM CENTRAL REVIEW OF 657 DUTCH CASES**  
**Marije Weidema**<sup>1</sup>; Melissa Hillebrandt-Roeffen<sup>1</sup>; Ingrid Desar<sup>1</sup>; Yvonne Versleijen-Jonkers<sup>1</sup>; Winette van der Graaf<sup>1</sup>; Uta Flucke<sup>2</sup>  
<sup>1</sup>Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; <sup>2</sup>Pathology, Radboud University Medical Center, Nijmegen, Netherlands
- Poster 005 3037976  
**THE ANGIOSARCOMA PROJECT: GENERATING THE GENOMIC LANDSCAPE OF A RARE SARCOMA THROUGH A NATIONWIDE PATIENT-DRIVEN INITIATIVE**  
Michael Dunphy<sup>1</sup>; Esha Jain<sup>1</sup>; Elana Anastasio<sup>1</sup>; Mary McGillicuddy<sup>1</sup>; Rachel Stoddard<sup>1</sup>; Beena Thomas<sup>1</sup>; Sara Balch<sup>1</sup>; Kristin Anderka<sup>2</sup>; Katie Larkin<sup>2</sup>; Niall Lennon<sup>2</sup>; Yen-Lin E. Chen<sup>3</sup>; Andrew Zimmer<sup>4</sup>; Esme O. Baker<sup>4</sup>; Simone Maiwald<sup>4</sup>; Jen Lapan<sup>4</sup>; Jason L. Hornick<sup>5</sup>; Chandrajit Raut<sup>5</sup>; George Demetri<sup>6</sup>; Eric S. Lander<sup>7</sup>; Todd Golub<sup>1</sup>; Nikhil Wagle<sup>6</sup>; **Corrie Painter**<sup>1</sup>  
<sup>1</sup>Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>2</sup>Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>3</sup>Massachusetts General Hospital, Boston, MA, USA; <sup>4</sup>Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>5</sup>Brigham and Women's Hospital, Boston, MA, USA; <sup>6</sup>Dana-Farber Cancer Institute, Cambridge, MA, USA; <sup>7</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Poster 006 3042503  
**A RETROSPECTIVE REVIEW OF PATIENTS WITH ANGIOSARCOMA TREATED IN BRITISH COLUMBIA**  
**Alannah Smrke**<sup>1</sup>; Jeremy Hamm<sup>1</sup>; Anand Karvat<sup>1</sup>; Christine Simmons<sup>1</sup>; Amirtha Srikanthan<sup>1</sup>  
<sup>1</sup>BC Cancer, Vancouver, BC, Canada
- Poster 008 3042562  
**NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH ENHANCED LOCAL CONTROL IN RADIATION-INDUCED ANGIOSARCOMA OF BREAST AND CHEST**  
**Audrey Michot**<sup>1</sup>; Marie Karanian<sup>2</sup>; Maryck Lae<sup>11</sup>; Romuald Wernert<sup>3</sup>; Marie-Pierre Sunyach<sup>4</sup>; Dimitri Tzanis<sup>5</sup>; Jean-Marie Guilloit<sup>6</sup>; Maria Rios<sup>7</sup>; Antoine Giraud<sup>8</sup>; François Le Loarer<sup>9</sup>; Jean-Yves Blay<sup>10</sup>; Eberhard Stoeckle<sup>1</sup>  
<sup>1</sup>Surgery, Institut Bergonié, Bordeaux, France; <sup>2</sup>Pathology, Leon Berard, Lyon, France; <sup>3</sup>Surgery, Institut de Cancerologie de l'Ouest, Angers, France; <sup>4</sup>Radiotherapy, Centre Leon Berard, Lyon, France; <sup>5</sup>Surgery, Institut Curie, Paris, France; <sup>6</sup>Surgery, Centre Francois Baclesse, Caen, France; <sup>7</sup>Medical Oncology, Institut de Cancerologie de Lorraine, Nancy, France; <sup>8</sup>Epidemiology and Clinical Research Unit, Institut Bergonié, Bordeaux, France; <sup>9</sup>Pathology, Institut Bergonié, Bordeaux, France; <sup>10</sup>Medical Oncology, Centre Leon Berard, Lyon, France; <sup>11</sup>Pathology, Institut Curie, Paris, France
- Poster 410 3042647  
**CHARACTERIZATION AND OUTCOMES OF VASCULAR SARCOMA PATIENTS ENROLLED ON PHASE 1 TRIALS**  
**Shiraj Sen**<sup>1</sup>; Kenneth Hess<sup>2</sup>; Ravi Vinod<sup>2</sup>; Anthony P. Conley<sup>2</sup>; David S. Hong<sup>2</sup>; Le Huang<sup>2</sup>; Tran B. Nguyen<sup>2</sup>; Shreyaskumar Patel<sup>2</sup>; Vivek Subbiah<sup>2</sup>  
<sup>1</sup>Sarah Cannon Research Institute at HealthONE, Denver, CO, USA; <sup>2</sup>UT MD Anderson Cancer Center, Houston, TX, USA

**Osteosarcoma/Chondrosarcoma/Chordoma**

Moderators: **Vicki Keedy** and **Kirsten Sundby Hall**

- Paper 038 3042790  
**STRESS MEDIATED TRANSLATIONAL CONTROL OF CHILDHOOD BONE SARCOMA METASTASIS**  
 Amal M. EL-Naggar<sup>1</sup>; Syam Somasekharan<sup>2</sup>; Hongwei Cheng<sup>2</sup>; Gian Luca Negri<sup>3</sup>; Didier Surdez<sup>4</sup>; Olivier Delattre<sup>4</sup>; **Poul H. Sorensen**<sup>1</sup>  
<sup>1</sup>Molecular Oncology, BC Cancer & University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>Vancouver Prostate Centre, Vancouver, BC, Canada; <sup>3</sup>Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; <sup>4</sup>Centre de recherche de l'Institut Curie, Paris, France
- Paper 039 3035462  
**PROSPECTIVE PHASE II STUDY OF SCANNED BEAM PROTON THERAPY FOR SPINE SARCOMAS**  
**David J. Konieczkowski**<sup>1</sup>; Yen-Lin E. Chen<sup>1</sup>; Karen De Amorim Bernstein<sup>1</sup>; Beow Yeap<sup>2</sup>; Matthew DiMaria<sup>3</sup>; Wenquin Jiang<sup>2</sup>; Nannette Thomas<sup>1</sup>; Suzanne L. McGovern<sup>4</sup>; John T. Mullen<sup>5</sup>; Joseph H. Schwab<sup>6</sup>; Francis Hornicek<sup>7</sup>; Thomas F. DeLaney<sup>1</sup>  
<sup>1</sup>Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>2</sup>Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; <sup>3</sup>Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA, USA; <sup>4</sup>Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>6</sup>Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA; <sup>7</sup>Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, MA, USA
- Paper 040 2993960  
**APATINIB FOR ADVANCED OSTEOSARCOMA AFTER FAILURE OF STANDARD MULTIMODAL THERAPY: AN OPEN LABEL PHASE 2 CLINICAL TRIAL(NCT02711007)**  
**Lu Xie**; Jie Xu; Xin Sun; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo  
 Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China
- Paper 041 3042511  
**SARC024: REGORAFENIB IN PATIENTS WITH REFRACTORY OSTEOSARCOMA**  
**Lara E. Davis**<sup>1</sup>; Christopher Ryan<sup>1</sup>; John Crowley<sup>2</sup>; Kristen Ganjoo<sup>3</sup>; Elizabeth Loggers<sup>4</sup>; Sant P. Chawla<sup>5</sup>; Mark Agulnik<sup>6</sup>; Michael B. Livingston<sup>7</sup>; Damon Reed<sup>8</sup>; Vicki Keedy<sup>9</sup>; Daniel A. Rushing<sup>10</sup>; Scott Okuno<sup>11</sup>; Denise Reinke<sup>12</sup>; Richard F. Riedel<sup>13</sup>; Steven Attia<sup>14</sup>; Leo Mascarenhas<sup>15</sup>; Robert Makj<sup>16</sup>  
<sup>1</sup>Oregon Health and Science University, Portland, OR, USA; <sup>2</sup>Cancer Research and Biostatistics, Seattle, WA, USA; <sup>3</sup>Stanford Cancer Institute, Stanford, CA, USA; <sup>4</sup>Seattle Cancer Care Alliance, Seattle, WA, USA; <sup>5</sup>Sarcoma Oncology Research Center, Santa Monica, CA, USA; <sup>6</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>7</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; <sup>8</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; <sup>9</sup>Vanderbilt University Medical Center, Nashville, TN, USA; <sup>10</sup>Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; <sup>11</sup>Mayo Clinic, Rochester, MN, USA; <sup>12</sup>SARC, Ann Arbor, MI, USA; <sup>13</sup>Duke University Medical Center, Durham, NC, USA; <sup>14</sup>Mayo Clinic, Jacksonville, FL, USA; <sup>15</sup>Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA; <sup>16</sup>Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY, USA

Paper 042 3042857  
**CABOZANTINIB IN PATIENTS WITH ADVANCED OSTEOSARCOMAS AND EWING SARCOMAS: A FRENCH SARCOMA GROUP (FSG)/ US NATIONAL CANCER INSTITUTE PHASE II COLLABORATIVE STUDY**  
**Antoine Italiano**<sup>1</sup>; Nicolas Penel<sup>2</sup>; Emmanuelle Bompas<sup>3</sup>; Sophie Piperno-Neumann<sup>4</sup>; Marina Pulido<sup>1</sup>; Natacha Entz-Werle<sup>5</sup>; Axel Le Cesne<sup>6</sup>; Christine Chevreau<sup>7</sup>; Florence Duffaud<sup>8</sup>; Isabelle Ray-Coquard<sup>9</sup>; Maud Toulmonde<sup>1</sup>; Carine Bellera<sup>1</sup>; Jean-Yves Blay<sup>9</sup>  
<sup>1</sup>Institut Bergonié, Bordeaux, France; <sup>2</sup>Centre Oscar Lambret, Lille, France; <sup>3</sup>Institut Cancerologie de l'Ouest, Nantes, France; <sup>4</sup>Institut Curie, Paris, France; <sup>5</sup>CHU de Strasbourg, Strasbourg, France; <sup>6</sup>Institut Gustave Roussy, Villejuif, France; <sup>7</sup>Oncopole Toulouse, Toulouse, France; <sup>8</sup>APHM Marseille, Marseille, France; <sup>9</sup>Centre Leon Berard, Lyon, France

Discussion – Katherine Janeway

10:30 am - 11:00 am **Morning Coffee Break** Salon de Cavalieri 1 & Gallery

11:00 am - 12:00 pm – NINA AXELRAD LECTURE – Salon del Cavalieri 2,3,4  
**Academic Clinical Trials in Sarcomas at the Time of Genomic Revolution**  
**Jean-Yves Blay**  
(Centre Léon BERARD Lyon, France)

12:00 pm - 1:00 pm **Lunch** Belle Arti & Garden Lobby

1:00 pm - 1:30 pm Salon del Cavalieri 2,3,4  
**Liddy Shriver Early Career Research Award**  
**Cigall Kadoch**

1:30 pm - 3:30 pm – SESSION 8 – Salon del Cavalieri 2,3,4  
**Soft Tissue Sarcoma: Biology**  
Moderators: **Torsten Nielsen** and **Poul Sorensen**

Paper 043 3042288  
**WHOLE GENOME SEQUENCING OF 1,111 SARCOMA PROBANDS REVEALS POT-1 AS A SARCOMA PREDISPOSITION GENE**  
**Mandy L. Ballinger**<sup>1</sup>; Mark Pinese<sup>1</sup>; Emma Rath<sup>1</sup>; Paul James<sup>2</sup>; Ajay Puri<sup>3</sup>; Nicolas Isambert<sup>4</sup>; Martin Tattersall<sup>5</sup>; Beatrice Seddon<sup>6</sup>; Ian Judson<sup>7</sup>; Winette van der Graaf<sup>7</sup>; Nicolas Penel<sup>8</sup>; Axel Lecesne<sup>9</sup>; Coonoor Chandrasekar<sup>10</sup>; Jean-Emmanuel Kurtz<sup>11</sup>; Joshua Schiffman<sup>12</sup>; R. Lor Randall<sup>12</sup>; Florence Duffaud<sup>13</sup>; Jin-Hee Ahn<sup>14</sup>; Rory Rickard<sup>15</sup>; Jean-Yves Blay<sup>16</sup>; Isabelle Ray-Coquard<sup>16</sup>; David M. Thomas<sup>1</sup>  
<sup>1</sup>Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; <sup>2</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; <sup>3</sup>Tata Memorial Hospital, Mumbai, India; <sup>4</sup>Centre Georges Francois Leclerc, Dijon, France; <sup>5</sup>University of Sydney, Sydney, New South Wales, Australia; <sup>6</sup>University College Hospital, London, United Kingdom; <sup>7</sup>The Royal Marsden NHS Foundation Trust, London, United Kingdom; <sup>8</sup>Centre Oscar Lambret, Lille, France; <sup>9</sup>Institut Gustav Roussy, Villejuif, France; <sup>10</sup>Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; <sup>11</sup>Hopitaux Universitaires de Strasbourg, Strasbourg, France; <sup>12</sup>Huntsman Cancer Institute, Salt Lake City, UT, USA; <sup>13</sup>La Timone University Hospital, Marseille, France; <sup>14</sup>Asan Medical Centre, Seoul, Korea (the Republic of); <sup>15</sup>Derriford Hospital, Plymouth, United Kingdom; <sup>16</sup>Centre Leon Berard, Lyon, France

- Paper 044 3042786  
**SEQCOMPLEX UNRAVELLING OMICS LANDSCAPE AND TARGETING ONCOGENIC PATHWAYS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS - AN INTEGRATED APPROACH**  
**Maud Toulmonde**<sup>1</sup>; Damien Geneste<sup>1</sup>; Stephanie Verbeke<sup>1</sup>; Julien Adam<sup>2</sup>; Fabiola Cecchi<sup>3</sup>; Banafshe Larijani<sup>4</sup>; Francois Bertucci<sup>6</sup>; Florent Petitprez<sup>5</sup>; Audrey Laroche<sup>1</sup>; Carlo Lucchesi<sup>1</sup>; Antoine Italiano<sup>1</sup>; Todd Hembrough<sup>3</sup>  
<sup>1</sup>Institut Bergonié, Bordeaux, France; <sup>2</sup>Gustave Roussy, Villejuif, France; <sup>3</sup>Nantomics, Rockville, MD, USA; <sup>4</sup>Fastbase Solutions Ltd, Plentzia, Spain; <sup>5</sup>UMRS 1138 - Centre de Recherche des Cordeliers, Paris, France; <sup>6</sup>Institut Paoli Calmettes, Marseille, France
- Paper 045 3010210  
**RATIONALES FOR TARGETING/CO-TARGETING LEIOMYOSARCOMA PATHWAYS: BIOLOGIC PROFILES IN 712 UTERINE OR SOFT-TISSUE LMS**  
**Inga-Marie Schaefer**<sup>1</sup>; Elizabeth G. Demicco<sup>2</sup>; Magdalena Matusiak<sup>3</sup>; Sebastian Bauer<sup>4</sup>; Frédéric Chibon<sup>5</sup>; Davis Ingram<sup>6</sup>; Jason L. Hornick<sup>1</sup>; Wei-Lien Wang<sup>6</sup>; Alexander J. Lazar<sup>6</sup>; Matt van de Rijn<sup>3</sup>; Jonathan A. Fletcher<sup>1</sup>  
<sup>1</sup>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>2</sup>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; <sup>3</sup>Department of Pathology, Stanford University Medical Center, Stanford, CA, USA; <sup>4</sup>Department of Medical Oncology, West German Cancer Center, Essen, Germany; <sup>5</sup>Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; <sup>6</sup>Departments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Paper 046 3042897  
**CHROMATIN STATE TRANSITIONS ASSOCIATED WITH PRC2 FUNCTIONAL LOSS DRIVE A DE-DIFFERENTIATED PHENOTYPE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS**  
**Veena Kochat**<sup>1</sup>; Ayush Raman<sup>2</sup>; Sharon Landers<sup>1</sup>; Christopher Terranova<sup>2</sup>; Chia-Chin Wu<sup>2</sup>; Xizeng Mao<sup>2</sup>; Davis Ingram<sup>3</sup>; Zachary Mulder<sup>1</sup>; Michelle Yeagley<sup>1</sup>; Hannah Beird<sup>2</sup>; Angela Bhalla<sup>1</sup>; John Slopis<sup>4</sup>; Ian McCutcheon<sup>5</sup>; Jianhua Zhang<sup>2</sup>; Phillip Futreal<sup>2</sup>; Wei-Lien Wang<sup>3</sup>; Alexander J. Lazar<sup>3</sup>; Kunal Rai<sup>2</sup>; Kiela E. Torres<sup>1</sup>  
<sup>1</sup>Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Genomic Medicine Department, MD Anderson Cancer Center, Houston, TX, USA; <sup>3</sup>Pathology, MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>NeuroOncology Department, MD Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>NeuroSurgery Department, MD Anderson Cancer Center, Houston, TX, USA
- Paper 047 3042069  
**TWIST BRIDGES P53 AND MDM2 AND REDUCES THE EFFICACY OF MDM2 INHIBITORS**  
Sara Piccinin<sup>1</sup>; Elena Doriguzzi Breatta<sup>1</sup>; Sara Lombardi<sup>1</sup>; Mattia Lombardi<sup>1</sup>; Flavia Pivetta<sup>1</sup>; Michela Armellin<sup>1</sup>; Camillo Rosano<sup>2</sup>; **Roberta Maestro**<sup>1</sup>  
<sup>1</sup>CRO Aviano, Aviano, Italy; <sup>2</sup>San Martino National Cancer Institute, Genova, Italy

Discussion – Judith Bovee

3:30 pm - 4:00 pm

**Afternoon Coffee Break**

Salon de Cavalieri 1 & Gallery

## Soft Tissue Sarcoma: Local Therapy

Moderators: **Kenneth Cardona** and **Alessandro Gronchi**

- Paper 048 3042386  
**LONG-TERM COMPARISON OF LOCAL RECURRENCE AFTER CONVENTIONAL AND INTENSITY-MODULATED RADIATION THERAPY FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY**  
**Joanna C. Yang**<sup>1</sup>; Michael Folkert<sup>2</sup>; Aimee M. Crago<sup>3</sup>; Sam S. Yoon<sup>3</sup>; Sam Singer<sup>3</sup>; Kaled Alektiar<sup>1</sup>  
<sup>1</sup>Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; <sup>3</sup>Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Paper 049 3028760  
**CAN WE CURE PATIENTS WITH ABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR? RESULTS OF A RETROSPECTIVE MULTICENTRIC STUDY ON 100 PATIENTS**  
**Charles Honoré**<sup>1</sup>; Jean-Baptiste Delhorme<sup>2</sup>; Elise Nassif<sup>3</sup>; Gwenael Ferron<sup>4</sup>; Emmanuelle Bompas<sup>5</sup>; Olivier Glehen<sup>6</sup>; Antoine Italiano<sup>7</sup>; Francois Bertucci<sup>8</sup>; Daniel Orbach<sup>9</sup>; Axel Le Cesne<sup>3</sup>; Jean-Yves Blay<sup>10</sup>; Christine Chevreau<sup>11</sup>; Olivier Mir<sup>3</sup>  
<sup>1</sup>Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; <sup>2</sup>General and Digestive Surgery, Strasbourg University Hospital, Strasbourg, France; <sup>3</sup>Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; <sup>4</sup>Surgery, Claudius Régaud Institute, Toulouse, France; <sup>5</sup>Medical Oncology, West Cancer Institute, Nantes, France; <sup>6</sup>Surgical Oncology, South Lyon University Hospital, Lyon, France; <sup>7</sup>Medical Oncology, Bergonié Institute, Bordeaux, France; <sup>8</sup>Medical Oncology, Paoli-Calmettes Institute, Marseilles, France; <sup>9</sup>SIREDO, Institut Curie, Paris, France; <sup>10</sup>Medical Oncology, Centre Léon Bérard, Lyon, France; <sup>11</sup>Medical Oncology, Claudius Régaud Institute, Toulouse, France
- Paper 050 3027816  
**ENHANCED RECOVERY AFTER SURGERY (ERAS) IN PATIENTS UNDERGOING SURGERY FOR SOFT TISSUE SARCOMA (STS): EARLY RESULTS OF A PROSPECTIVE QUALITY IMPROVEMENT PROTOCOL**  
**Heather Lyu**<sup>1</sup>; Lily V. Saadat<sup>1</sup>; Elizabeth H. Baldini<sup>2</sup>; Jiping Wang<sup>1</sup>; Matthias Stopfkuchen-Evans<sup>1</sup>; Ronald Bleday<sup>1</sup>; Monica Bertagnolli<sup>1</sup>; Chandrajit Raut<sup>1</sup>  
<sup>1</sup>Brigham and Women's Hospital, Boston, MA, USA; <sup>2</sup>Dana Farber Cancer Institute, Boston, MA, USA
- Paper 051 3042593  
**DEVELOPMENT OF A DYNAMIC PROGNOSTIC NOMOGRAM TO PREDICT OVERALL SURVIVAL DURING FOLLOW-UP IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA PATIENTS TREATED WITH SURGERY**  
**Dario Callegaro**<sup>1</sup>; Rosalba Miceli<sup>2</sup>; Sylvie Bonvalot<sup>3</sup>; Peter Ferguson<sup>4</sup>; Dirk Strauss<sup>5</sup>; Antonin Levy<sup>6</sup>; Anthony M. Griffin<sup>4</sup>; Andrew J. Hayes<sup>5</sup>; Silvia Stacchiotti<sup>7</sup>; Cécile Le Péchoux<sup>6</sup>; Myles J. Smith<sup>5</sup>; Marco Fiore<sup>1</sup>; Angelo Paolo Dei Tos<sup>8</sup>; Henry Smith<sup>5</sup>; Charles Catton<sup>9</sup>; Paolo Casali<sup>10</sup>; Jay Wunder<sup>4</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Surgery, Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Clinical Epidemiology and Trial Organisation, Istituto Nazionale Tumori, Milan, Italy; <sup>3</sup>Surgery, Institut Curie, PSL Research University, Paris, France; <sup>4</sup>Surgery, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; <sup>5</sup>Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; <sup>6</sup>Radiation Oncology, Gustave Roussy Cancer Campus, Paris Sud University, Villejuif, France; <sup>7</sup>Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy; <sup>8</sup>Pathology, General Hospital of Treviso, Treviso, Italy; <sup>9</sup>Radiation Oncology, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; <sup>10</sup>Oncology and Hemato-Oncology, Istituto Nazionale Tumori, University of Milan, Milan, Italy

Paper 052

3042509

**THE IMPACT OF UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS:  
A MULTI-INSTITUTIONAL PROPENSITY SCORE ANALYSIS FROM THE US-SARCOMA  
COLLABORATIVE**

**Mohammad Zaidi**<sup>1</sup>; Cecilia G. Ethun<sup>1</sup>; Yuan Liu<sup>2</sup>; Thuy B. Tran<sup>3</sup>; George Poultsides<sup>3</sup>; Valerie P. Grignol<sup>4</sup>; J. H. Howard<sup>4</sup>; Meena Bedi<sup>5</sup>; Harveshp Mogal<sup>6</sup>; Jennifer Tseng<sup>7</sup>; Kevin K. Roggin<sup>7</sup>; Konstantinos Chouliaras<sup>8</sup>; Konstantinos Votanopoulos<sup>8</sup>; Darren Cullinan<sup>9</sup>; Ryan C. Fields<sup>9</sup>; Shervin Oskouei<sup>1</sup>; Nickolas Reimer<sup>1</sup>; David Monson<sup>1</sup>; Kenneth Cardona<sup>1</sup>  
<sup>1</sup>Surgery, Emory University, Atlanta, GA, USA; <sup>2</sup>Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA; <sup>3</sup>Surgery, Stanford University, Atlanta, GA, USA; <sup>4</sup>Surgery, The Ohio State University, Columbus, OH, USA; <sup>5</sup>Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>6</sup>Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>7</sup>Surgery, University of Chicago Medicine, Chicago, IL, USA; <sup>8</sup>Surgery, Wake Forest University, Winston-Salem, NC, USA; <sup>9</sup>Surgery, Washington University School of Medicine, St. Louis, MO, USA

Discussion – Rebecca Gladdy

5:30 pm - 6:00 pm

**CTOS Business Meeting**

*Salon del Cavaliere 2,3,4*